What does the FTC's "second request" mean for the acquisition of CTP-656?

A "second request" from the FTC signifies that the agency is conducting a more in-depth antitrust review of the proposed acquisition. It typically means the waiting period for the Hart-Scott-Rodino Act is extended, and the FTC requires more detailed information and analysis before potentially granting approval.

Could the FTC's second request block the acquisition?

While a second request indicates increased scrutiny, it does not automatically mean the deal will be blocked. Vertex intends to cooperate with the FTC, and the outcome will depend on the antitrust concerns the FTC identifies and how Vertex addresses them. However, it does increase the uncertainty and could potentially lead to delays or require modifications to the deal.

What is Vertex's commitment to the FTC review?

Vertex has stated its intention to work cooperatively with the FTC throughout its review of the transaction. This suggests they are prepared to provide the necessary information and engage constructively with the agency.

Where can I find more information about the acquisition and Concert Pharmaceuticals?

Investors are urged to read Concert Pharmaceuticals' proxy statement, which contains important information about the proposed asset sale. This document, along with other relevant filings, is available on the SEC's website (www.sec.gov) and may also be found on Concert's investor relations website (www.concertpharma.com) or by contacting Concert directly.

VRTX 8-K SEC Disclosure

Summary

Vertex Pharmaceuticals Inc. (VRTX) disclosed on May 22, 2017, that the U.S. Federal Trade Commission (FTC) has issued a "second request" for additional information regarding its pending acquisition of CTP-656 and related cystic fibrosis assets from Concert Pharmaceuticals, Inc. This action, under the Hart-Scott-Rodino Antitrust Improvements Act, signifies that the FTC is conducting a more in-depth review of the transaction's antitrust implications. While this represents a procedural step in the regulatory approval process, it could potentially extend the timeline for closing the acquisition. Vertex has indicated its intention to cooperate fully with the FTC's review. Investors should monitor any further developments from the FTC and Vertex regarding this acquisition, as regulatory approval is a key factor for the successful integration of Concert's assets and the potential impact on Vertex's cystic fibrosis pipeline.

Key Highlights

1FTC issues "second request" for additional information on the acquisition of Concert Pharmaceuticals' cystic fibrosis assets (CTP-656).
2The request is made under the Hart-Scott-Rodino Antitrust Improvements Act, indicating a more detailed antitrust review.
3Vertex Pharmaceuticals intends to cooperate fully with the FTC's review process.
4The acquisition is subject to regulatory approval, and the second request may extend the timeline for closing.
5Concert Pharmaceuticals' shareholders will vote on the proposed asset purchase agreement.
6Investors are advised to review Concert's proxy statement for important details regarding the transaction.

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (May 22, 2017)

Summary

Key Highlights

Frequently Asked Questions